new glp 1 agonist for weight loss Hitting the Triple G Spot: The Triple G new glp 1 agonist In
Description
A recent meta-analysis involving 32,884 patients from 19 randomized controlled trials further confirmed a 23% reduction in all-cause mortality associated with GLP-1RAs use (OR = 0.77) (Rivera et al., 2024)
Stimulation of gluconeogenesis by long chain fatty acids and glucagon
Rubino, N
P = 0.04), a main contributor to the reduction of 3-MACE composite endpoint (253)
Wegovys approval was based on the STEP study
)
